Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXS-05 for Prevention of Relapse of Depressive Symptoms
NCT06223880Phase 4Recruiting
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Dec 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dextromethorphan + bupropion in major depressive disorder (MDD), sponsored by Axsome Therapeutics, Inc.. Started Dec 2023; status: recruiting.
02
Drugs
dextromethorphan + bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06223880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223880.